Skip to main content

Table 1 Baseline characteristics of the study population stratified according to the presence or absence of nonalcoholic fatty liver disease

From: Non–small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?

Characteristics

Non-NAFLD

NAFLD

P value

Patient characteristics

Patients, n

361

118

 

Gender, n (%)

  

0.064

 Male

310 (64.7%)

109(22.8%)

 

 Female

51 (10.6%)

9 (1.9%)

 

Age, No. (%)

  

0.780

  < 65

195 (40.7%)

62 (12.9%)

 

  ≥ 65

166 (34.7%)

56 (11.7%)

 

Body mass index (kg/m2)*, n (%)

  

 < 0.001

  ≤ Median

308 (64.3%)

83 (17.3%)

 

  > Median

53 (11.1%)

35 (7.3%)

 

ECOG performance status

  

0.983

 0

135 (28.2%)

44 (9.2%)

 

  ≥ 1

226 (47.2%)

74 (15.4%)

 

Diabetes, n (%)

31 (6.5%)

14 (2.9%)

0.289

Hypertension, n (%)

110 (23%)

42 (8.8%)

0.299

Smoking, n (%)

190 (39.7%)

70 (14.6%)

0.205

Hyperlipidemia, n (%)

109 (22.8%)

39 (8.1%)

0.560

Hemoglobin (g/L), mean (SD)

123.7 (16.2)

124.4 (16.4)

0.674

Blood urea nitrogen (mmol/L), mean (SD)

5.3 (1.7)

5.6 (1.9)

0.105

Serum creatinine (umol/L), mean (SD)

72.0 (14.7)

73.0 (15.0)

0.530

Total bilirubin (mg/dL), mean (SD)

10.5 (4.8)

12.8 (6.1)

 < 0.001

Alanine aminotransferase (U/L), mean (SD)

24.5 (28.3)

27.78 (26.9)

0.281

Aspartate aminotransferase (U/L), mean (SD)

23.4 (14.9)

26.4 (28.9)

0.139

Alkaline phosphatase (U/L), mean (SD)

100.7 (59.1)

102.8 (49.4)

0.733

γ-glutamyl transpeptadase (U/L), mean (SD)

47.4 (68.4)

58.0 (60.4)

0.133

Albumin (g/L), mean (SD)

38.6 (4.9)

37.6 (4.5)

0.058

Albumin/Globulin ratio, mean (SD)

1.5 (1.2)

1.3 (0.3)

0.144

lactic dehydrogenase (U/L), mean (SD)

236.9 (115.8)

229.2 (95.8)

0.516

Pathological types, n (%)

  

0.540

 adenocarcinoma

169 (35.3%)

50 (10.4%)

 

 squamous carcinoma

169 (35.3%)

62 (12.9%)

 

 other

23 (4.8%)

6 (1.3%)

 

Types of ICIs, n (%)

  

0.727

 PD-1 antibody

333 (69.5%)

110 (23%)

 

 PD-L1 antibody

28 (5.8%)

8 (1.7%)

 

Stages, n (%)

  

0.998

 Stage III

260 (54.3%)

85 (17.7%)

 

 Stage IV

101 (21.1%)

33 (6.9%)

 
  1. Abbreviation: NAFLD Patients with non-alcoholic fatty liver disease, Non-NAFLD Patients without non-alcoholic fatty liver disease, SD Standard deviation, ICIs Immune checkpoint inhibitors, PD-1 programmed cell death-1, PD-L1 Programmed cell death-ligand 1
  2. *Median body mass index is 25 kg/m2
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us